BioSpace News Archive

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced positive initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) study of paltusotine, an oral, once-daily investigational compound being developed for the treatment of acromegaly and CS.

CymaBay Therapeutics, Inc. announced the grant of inducement awards to four employees on December 15, 2023 in connection with the employees’ commencement of employment at CymaBay.

ADMA Biologics, Inc. announced the Company has executed a definitive credit agreement with Ares Management credit funds for $135 million in total senior secured credit facilities, including a $72.5 million asset-backed revolving credit facility and a $62.5 million term loan.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen, an investigational prophylactic treatment for hereditary angioedema (HAE).

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference.

bluebird bio, Inc. announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock.

Acadia Pharmaceuticals Inc. announced that on December 13, 2023, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 33,647 shares of common stock and 20,146 restricted stock units to eight new employees under Acadia’s 2023 Inducement Plan.

Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced the promotion of John Gillard, our Chief Financial Officer, to President and Chief Executive Officer, effective immediately.

Carina Biotech Limited (Carina), a cell therapy immuno-oncology company, today announced the dosing of the first patient in a Phase 1/2a clinical trial of its LGR5-targeted CAR-T cell therapy candidate CNA3103 for the treatment of adult patients with metastatic colorectal cancer (mCRC).

Allay Therapeutics, Inc. (Allay) today announced that they have entered into a license agreement with Maruishi Pharmaceutical Co., Ltd. (Maruishi), providing Maruishi with exclusive rights to develop and commercialize Allay’s lead investigational drug candidate, ATX101, and other ultra-sustained analgesic implantable drug candidates for acute pain in Japan.